MONTREAL and CHARLOTTE, North Carolina, April 15, 2022 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company specializing in the development and commercialization of innovative cardiovascular drugs, today announced that Milestone’s Compensation Committee has awarded a new employee $65,000 incentive stock options at an exercise price per share of $6.85the closing price of Milestone common stock on April 1, 2022 and another new employee 36,000 incentive stock options at an exercise price per share of $6.93, the closing price of Milestone common stock on April 11, 2022. The awards were made pursuant to NASDAQ’s incentive grant exception as a component of new hire compensation. The incentive grants have been approved by Milestone’s Compensation Committee and are made as incentive material for each employee’s acceptance of employment with the company in accordance with NASDAQ listing rule 5635(c). )(4).
The stock options each have a term of 10 years and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the relevant employee’s new hire date and 2. 0833% of the initial number of shares vesting each month thereafter. the same day of the month as the employee’s new hire date until fully vested, subject to the employee’s continuous service with the company through the applicable vesting dates .
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular drugs. Milestone’s lead product candidate, etripamil, is currently in a Phase 3 clinical program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and a Phase 2 proof-of-concept trial for the treatment patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and United States. For more information, visit www.milestonepharma.com and follow the company on Twitter at @MilestonePharma.
SOURCEMilestone Pharmaceuticals, Inc.